Abbott Laboratories: The Sales Pitch Was Less Nursing-Home Paperwork

Whistleblower Justice Network

In the Abbott Laboratories False Claims Act settlement announced in 2012, the company agreed to pay $800 million to resolve civil allegations that Depakote promotion and kickbacks caused false government healthcare claims. The case reached into sales training, pharmacy contracts and the materials used to influence prescribing. If you know how a drug’s sales message gets built, you may recognize the decisions that happen long before anyone sends the government a bill.

One alleged selling point was less nursing-home paperwork. The government said Abbott promoted Depakote for behavioral disturbances in dementia patients by telling nursing homes they could avoid restrictions that applied to antipsychotic drugs. We see the absurdity in that pitch: safeguards for nursing-home residents became paperwork to sell around.

How Depakote Promotion Reached Government Reimbursement

The government’s civil case connected Abbott’s promotion to prescriptions for uses that government programs did not cover, and its alleged kickbacks to the prescriptions that followed. In its May 7, 2012 announcement, the Justice Department said the alleged marketing and payment practices caused false claims to reach Medicare, Medicaid, TRICARE and other federal health programs.

The civil allegations covered promotion from 1998 through 2008. They included behavioral disturbances in dementia patients, psychiatric conditions in children and adolescents, and schizophrenia, among other uses. The government alleged that Abbott made false or misleading statements about safety, effectiveness, dosing and cost-effectiveness. The government alleged that some promoted uses were not medically accepted uses for which federal and state Medicaid programs covered Depakote.

That is the connection between the sales campaign and the claim for government money. The government alleged that Abbott caused the claims through its conduct upstream of billing. For someone in pharmaceutical sales or pharmacy contracting, the relevant knowledge is the message that drove a prescription or the payment that encouraged it. The government also alleged that Abbott paid health care professionals and long-term-care pharmacy providers to promote or prescribe Depakote, and improperly influenced company-sponsored continuing medical education.

The Nursing-Home Sales Pitch

In the agreed statement of facts filed with its criminal plea, Abbott admitted maintaining a specialized sales force from 1998 through 2006 to promote Depakote for agitation and aggression in elderly dementia patients, despite the absence of credible scientific evidence that it was safe and effective for that use. At the time described in the announcement, Depakote’s approved uses were epileptic seizures, bipolar mania and migraine prevention. The government said Abbott discontinued a dementia trial in 1999 because elderly participants experienced increased adverse events, including excessive sleepiness, dehydration and loss of appetite.

The civil allegations explain the commercial pitch. Nursing homes faced restrictions on antipsychotic drugs intended to prevent unnecessary medication. Abbott allegedly sold Depakote as a way to avoid the administrative work and costs attached to those restrictions. The whistleblower’s complaint went further, alleging that sales pitches promised nursing staff less routine behavior tracking and fewer flow records.

Less paperwork. For the people selling the drug, that was a benefit to put in front of the facility.

The Training Behind Closed Doors

The whistleblower’s complaint alleged that new sales recruits heard corporate trainers tell them to promote Depakote only for approved uses. Then the recruits moved into another room, the door closed, and an experienced neuroscience sales representative allegedly told them to disregard those instructions. Their main opportunity, the complaint alleged, was selling into the long-term-care market for agitation and aggression in dementia patients.

That alleged split makes the people in the training room important. According to the complaint, the formal instruction and the instruction employees were expected to follow told different stories about the same sales job.

Pharmacy Advice With a Manufacturer’s Sales Message

Long-term-care pharmacy providers supplied another route into nursing homes. The government alleged that Abbott paid those providers to encourage Depakote promotion and prescribing. Its announcement describes contracts tying rebates to increased Depakote use in the homes the pharmacies served, along with programs training consultant pharmacists to recommend the drug for the unapproved use.

The complaint alleged that Abbott put Omnicare or PharMerica names and logos on promotional pocket guides to make them look pharmacy-sponsored. It alleged that pharmacy consultants became a sales force for Abbott’s off-label promotion under that cover.

The complaint also alleged that pharmacy-branded training videos presented fictional patient cases in which the care team chose Depakote for an elderly patient’s aggression associated with dementia. The alleged sales message arrived dressed as pharmacy guidance. Someone who knew who developed the material, who sponsored it and who distributed it could see the commercial relationship behind the logo.

Schizophrenia Studies and the Sales Message That Continued

Abbott also admitted in the criminal case’s agreed statement of facts that it marketed Depakote for schizophrenia from 2001 through 2006. According to the Justice Department, both company-funded studies failed to meet their main goals. The second failed to show a statistically significant treatment difference between antipsychotics taken with Depakote and antipsychotics taken alone.

Abbott waited nearly two years to tell its own sales force about the second study’s results, then another two years to publish them. During that time, it continued the off-label promotion, according to the government’s account of the agreed facts.

We see a particularly revealing gap there: the company had results that undermined the pitch while the people delivering it had not been told. For a pharmaceutical insider, the dates on study results and internal sales communications can explain how a message survived the evidence against it.

Four Qui Tam Cases and the Civil Settlement

Four whistleblower cases in the Western District of Virginia fed into the Abbott civil resolution. The Justice Department announced one civil settlement resolving those cases, with payments to the federal government and participating states.

The whistleblowers were collectively to receive $84 million from the federal share, according to that announcement. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The Pharmacy Relationship Appears in Other Drug Cases

Johnson & Johnson’s civil settlement in 2013 was larger than Abbott’s Depakote resolution: $1.72 billion, also involving allegations of drug promotion and payments to prescribers and pharmacies. The government alleged promotion involving Risperdal, Invega and Natrecor, along with payments to physicians and Omnicare. The recurring issue was who influenced the prescription, and who paid for that influence.

What Was Abbott’s Infant-Formula Settlement About?

Abbott’s September 14, 2026 False Claims Act settlement resolved allegations concerning contaminated infant formula and nutritional-therapy products. Abbott agreed to a civil settlement of $384,999,040 over manufacturing-compliance allegations, with a collective whistleblower award of $69 million from the federal settlement.

That was a separate case from the Depakote resolution. The distinction matters to an insider: one concerned how products were made, the other how a drug was promoted and prescribed.

What the Sales Records Could Show

The Abbott complaint identified a particularly concrete form of evidence connecting sales activity to management knowledge: the representatives’ call notes. It alleged that the notes were regularly uploaded to Abbott’s mainframe computers, where district managers and sales and marketing management used them to track the success of off-label sales calls.

That allegation brings together the person making the pitch and the people measuring its success. A sales representative may understand what a call note meant because they heard the training. A pharmacy employee may recognize the pocket guide or the training video. Someone handling contracts may understand how a rebate depended on prescribing volume.

You Know How the Drug Was Sold

If you saw the sales instructions, pharmacy incentives or study results behind a drug’s promotion, speak to one of our Whistleblower Experts about the government payments they affected. We work beside you to build your strongest pharmaceutical whistleblower case and bring in pharmaceutical fraud whistleblower lawyers who understand promotion, prescribing and reimbursement. You bring the view from inside the business; we bring the expertise and partnership to pursue it with you.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365